指南与共识心血管介入CTMRPET

心脏立体定向体部放疗治疗难治性室性心动过速的专家共识建议

Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia.
指南 / 共识 · Heart Rhythm · 2021-08-08

共识强调该治疗仍属实验性,应在临床试验中优先开展,并限于优化药物治疗后仍反复发作且已接受导管消融或有禁忌的患者,需在具备心律失常和立体定向放疗经验的中心进行,且靶区勾画需多学科协作。

要点

  • CSBRT目前仍为实验性治疗,应优先在临床试验中开展。
  • 患者选择:难治性VT,已优化抗心律失常药物,且既往导管消融或存在禁忌。
  • 靶区勾画复杂,需心脏科/电生理、放疗科、医学物理、放射科及核医学科多学科协作。

局限性

  • 专家共识基于改良德尔菲法,非系统评价或高级别证据。
  • 参与专家仅来自德国和瑞士,代表性有限。
  • 共识声明本身不提供CSBRT的具体技术参数或疗效数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Ventricular tachycardia (VT) is a potentially lethal complication of structural heart disease. Despite optimal management, a subgroup of patients continue to suffer from recurrent VT. Recently, cardiac stereotactic body radiotherapy (CSBRT) has been introduced as a treatment option in patients with VT refractory to antiarrhythmic drugs and catheter ablation.

OBJECTIVE: The purpose of this study was to establish an expert consensus regarding the conduct and use of CSBRT for refractory VT.

METHODS: We conducted a modified Delphi process. Thirteen experts from institutions from Germany and Switzerland participated in the modified Delphi process. Statements regarding the following topics were generated: treatment setting, institutional expertise and technical requirements, patient selection, target volume definition, and monitoring during and after CSBRT. Agreement was rated on a 5-point Likert scale. The strength of agreement was classified as strong agreement (≥80%), moderate agreement (≥66%) or no agreement (<66%).

RESULTS: There was strong agreement regarding the experimental status of the procedure and the preference for treatment in clinical trials. CSBRT should be conducted at specialized centers with a strong expertise in the management of patients with ventricular arrhythmias and in stereotactic body radiotherapy for moving targets. CSBRT should be restricted to patients with refractory VT with optimal antiarrhythmic medication who underwent prior catheter ablation or have contraindications. Target volume delineation for CSBRT is complex. Therefore, interdisciplinary processes that should include cardiology/electrophysiology and radiation oncology as well as medical physics, radiology, and nuclear medicine are needed. Optimal follow-up is required.

CONCLUSION: Prospective trials and pooled registries are needed to gain further insight into this promising treatment option for patients with refractory VT.

来源:Heart Rhythm,查看原文。版权归原作者所有。

引用

  1. Krug D, Blanck O, Andratschke N, et al. Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia. Heart Rhythm. 2021. PMID: 34380072. doi:10.1016/j.hrthm.2021.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。